Story perspectives

Insurers Restrict GLP-1s as Obesity Costs Surge, Safety Concerns Rise

7/25/2026

Summary

Story summary

University of Mississippi researchers say insurers still restrict GLP-1 drugs such as Ozempic, Wegovy and Zepbound.
The Institute for Clinical and Economic Review finds GLP-1s cost-effective but over $821 million budget, and says Sujith Ramachandran warns the 40 % U.S. obesity rate could push insurer spending into billions despite no proof of long-term savings.
Doctoral candidate Liang-Yuan Lin warns compounded GLP-1s lack FDA approval and may contain unsafe ingredients.

1 of 1

Story summary

University of Mississippi researchers say insurers still restrict GLP-1 drugs such as Ozempic, Wegovy and Zepbound.
The Institute for Clinical and Economic Review finds GLP-1s cost-effective but over $821 million budget, and says Sujith Ramachandran warns the 40 % U.S. obesity rate could push insurer spending into billions despite no proof of long-term savings.
Doctoral candidate Liang-Yuan Lin warns compounded GLP-1s lack FDA approval and may contain unsafe ingredients.